^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TC-110

    i
    Other names: TC-110
    Associations

    News

    Trials
    Company:
    Adaptimmune
    Drug class:
    CD19 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=6, Completed, TCR2 Therapeutics | Recruiting --> Completed | N=120 --> 6 | Trial completion date: Apr 2024 --> Feb 2023 | Trial primary completion date: Apr 2022 --> Feb 2023
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • fludarabine IV • TC-110